Journal
Neuro-Oncology Advances
Publication Date
1-1-2023
Volume
5
Issue
1
First Page
vdac183
Document Type
Open Access Publication
DOI
10.1093/noajnl/vdac183
Rights and Permissions
Benedito A Carneiro, Kyriakos P Papadopoulos, John H Strickler, Andrew B Lassman, Saiama N Waqar, Young Kwang Chae, Jyoti D Patel, Einat Shacham-Shmueli, Karen Kelly, Mustafa Khasraw, Christine M Bestvina, Ryan Merrell, Kevin Huang, Harisha Atluri, Peter Ansell, Rachel Li, Janet Jin, Mark G Anderson, Edward B Reilly, Gladys Morrison-Thiele, Kalpesh Patel, Randy R Robinson, Martha R Neagu Aristide, Hui K Gan, Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma, Neuro-Oncology Advances, Volume 5, Issue 1, January-December 2023, vdac183, https://doi.org/10.1093/noajnl/vdac183. https://academic.oup.com/noa/article/5/1/vdac183/6955797?login=true. © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
Recommended Citation
Carneiro, Benedito A; Waqar, Saiama N; and et al., "Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma." Neuro-Oncology Advances. 5, 1. vdac183 (2023).
https://digitalcommons.wustl.edu/oa_4/1455
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
